PC
AUPH icon

Polar Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

Polar Capital’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,312,723
Closed -$17.7M – 285
2019
Q3 		$17.7M Hold
3,312,723
– – 0.16% 156
2019
Q2 		$21.8M Hold
3,312,723
– – 0.19% 143
2019
Q1 		$21.5M Hold
3,312,723
– – 0.2% 143
2018
Q4 		$22.6M Buy
3,312,723
+501,207
+18% +$2.89M 0.24% 125
2018
Q3 		$18.7M Buy
2,811,516
+211,316
+8% +$1.19M 0.16% 153
2018
Q2 		$14.6K Buy
2,600,200
+100,200
+4% +$559K 0.09% 173
2018
Q1 		$13M Buy
2,500,000
+200,000
+9% +$1.07M 0.13% 167
2017
Q4 		$10.4M Buy
2,300,000
+681,648
+42% +$3.78M 0.11% 164
2017
Q3 		$10.1M Buy
1,618,352
+435,080
+37% +$2.74M 0.11% 160
2017
Q2 		$7.25M Buy
+1,183,272
New +$7.97M 0.1% 167

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Polar Capital's AUPH Position: Q4 2019 in Review

Polar Capital sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2019, closing a stake of 3,312,723 shares — an estimated $17.7M sold.

Polar Capital first reported a position in AUPH in Q2 2017 and held it in 10 quarters. The position peaked at $22.6M in Q4 2018. 115 funds tracked by Wall St. Rank hold AUPH as of Q4 2019.

  • Polar Capital reported no remaining Aurinia Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Polar Capital sold 3,312,723 Aurinia Pharmaceuticals shares in Q4 2019, an estimated $17.7M.
  • Polar Capital first reported a position in Aurinia Pharmaceuticals in Q2 2017 and held it in 10 quarters.
  • Polar Capital's Aurinia Pharmaceuticals position peaked at $22.6M in Q4 2018.
  • 115 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2019.

Based on Polar Capital's 13F filing for Q4 2019, filed 14 Feb 2020.